	US 11,988,676 B2
	Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
Timothy E. Van Meter, Richmond, VA (US)
Assigned to BRAINBOX SOLUTIONS, INC., Richmond, VA (US)
Appl. No. 16/763,794
Filed by BRAINBOX SOLUTIONS, INC., Richmond, VA (US)
PCT Filed Nov. 15, 2018, PCT No. PCT/US2018/061372 § 371(c)(1), (2) Date May 13, 2020, PCT Pub. No. WO2019/099732, PCT Pub. Date May 23, 2019.
Claims priority of provisional application 62/587,272, filed on Nov. 16, 2017.
Prior Publication US 2020/0355701 A1, Nov. 12, 2020
Int. Cl. G01N 33/68 (2006.01); C07K 16/28 (2006.01); C07K 16/36 (2006.01)

CPC G01N 33/6896 (2013.01) [C07K 16/2803 (2013.01); C07K 16/36 (2013.01); G01N 33/6848 (2013.01); G01N 2333/705 (2013.01); G01N 2333/755 (2013.01); G01N 2333/825 (2013.01)]

14 Claims

1. A method of detecting two or more protein biomarkers, or fragments thereof, in a biofluid sample obtained from a subject having, or suspected of having, a traumatic brain injury, the method comprising the steps of:

A) obtaining the biofluid sample from the patient; and

B) detecting von Willebrand Factor (vWF) and Astrotactin 2 (ASTN2) in the biofluid sample by an assay or mass spectrometry.